Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy

Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy

Direct-acting antivirals (DAAs) for hepatitis C virus (HCV) may induce hepatitis B virus (HBV) reactivations in co-infected patients, whose dynamics and outcomes could depend on the phase of HBV infection. We investigated HBsAg and HBV-DNA kinetics in fifteen untreated HBeAg Negative Infection (ENI)...

Full description

Bibliographic Details
Main Authors:	Piero Colombatto, Elena Palmisano, Gabriele Ricco, Daniela Cavallone, Filippo Oliveri, Barbara Coco, Antonio Salvati, Veronica Romagnoli, Lidia Surace, Marialinda Vatteroni, Mauro Pistello, Agostino Virdis, Ferruccio Bonino, Maurizia Rossana Brunetto
Format:	Article
Language:	English
Published:	MDPI AG 2022-03-01
Series:	Journal of Clinical Medicine
Subjects:	hepatitis B virus hepatitis C virus co-infection direct acting antivirals chronic hepatitis B HBeAg negative infection
Online Access:	https://www.mdpi.com/2077-0383/11/5/1406

Similar Items

HBeAg-Negative/Anti-HBe-Positive Chronic Hepatitis B: A 40-Year-Old History
by: Ferruccio Bonino, et al.
Published: (2022-07-01)

Quantitative HBsAg and Qualitative HBeAg Predicts Intrauterine Placental Infection and Umbilical Blood Cord in Pregnant Women
by: Erry Gumilar Dachlan, et al.
Published: (2020-10-01)

The Complex Role of HBeAg and Its Precursors in the Pathway to Hepatocellular Carcinoma
by: Kiyasha Padarath, et al.
Published: (2023-03-01)

Coexistence of HBsAg/Anti-HBs and HBeAg/Anti-HBe in Sudanese Patients with Chronic Hepatitis B Virus Infection: A Cross-Sectional Study
by: Taqwa Hashim, et al.
Published: (2023-12-01)

Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks
by: Xiaomei Wang, et al.
Published: (2020-10-01)

Combination of Peginterferon α-2b (12 kDa) and Lamivudine in difficult-to-treat chronic hepatitis B-an Indian experience
by: Deepak N. Amarapurkar, et al.
Published: (2005-01-01)

HBV-RNA, Quantitative HBsAg, Levels of HBV in Peripheral Lymphocytes and HBV Mutation Profiles in Chronic Hepatitis B
by: Yael Gozlan, et al.
Published: (2022-03-01)

CLINICAL RELEVANCE OF PRECORE MUTATIONS OF HEPATITIS B VIRUS IN CHRONIC LIVER DISEASE
by: Chaloska Ivanova Viktorija, et al.
Published: (2014-07-01)

Clinical relevance of precore mutations of hepatitis B virus in chronic liver disease
by: Chaloska-Ivanova Viktorija, et al.
Published: (2014-07-01)

Early Treatment Consideration in Patients with Hepatitis B ‘e’ Antigen-Positive Chronic Infection: Is It Time for a Paradigm Shift?
by: Apostolos Koffas, et al.
Published: (2022-04-01)

What is the reason of elevated alanine aminotransferase level in HBeAg negative patients with low viremia: NAFLD or chronic hepatitis?
by: Kadir Demir, et al.
Published: (2007-04-01)

Comparison of evolutionary patterns of different HBeAg status in HBV genotype B and C
by: Cai Ying, et al.
Published: (2015-12-01)

The human C-type lectin 18 is a potential biomarker in patients with chronic hepatitis B virus infection
by: Tsung-Yu Tsai, et al.
Published: (2018-07-01)

Maternal transmission risk and antibody levels against hepatitis B virus e antigen in pregnant women
by: Ling-Ling Lu, et al.
Published: (2014-11-01)

Frequency of HBsAg in pregnant women in Gorgan, Iran
by: Cheraghali F (MD), et al.
Published: (2012-01-01)

Compositional changes of PBL population in patients with chronic hepatitis B virus infection
by: Khabiri Alireza, et al.

Naturally Occurring Mutations within HBV Surface Promoter II Sequences Affect Transcription Activity, HBsAg and HBV DNA Levels in HBeAg-Positive Chronic Hepatitis B Patients
by: Ran Hao, et al.
Published: (2019-01-01)

The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions
by: Ott Jördis J, et al.
Published: (2012-06-01)

A novel nomogram for predicting HBeAg seroclearance in HBeAg-positive chronic hepatitis B patients treated with nucleos(t)ide analogues
by: Yan Gu, et al.
Published: (2024-01-01)

Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections
by: Weiqiang Gan, et al.
Published: (2020-12-01)

The Circulating miRNA Profile of Chronic Hepatitis D and B Patients Is Comparable but Differs from That of Individuals with HBeAg-Negative HBV Infection
by: Daniela Cavallone, et al.
Published: (2023-11-01)

Corrigendum: Difference of gut microbiota between patients with negative and positive HBeAg in chronic hepatitis B and the effect of tenofovir alafenamide on intestinal flora
by: Jianfei Long, et al.
Published: (2023-11-01)

Difference of gut microbiota between patients with negative and positive HBeAg in chronic hepatitis B and the effect of tenofovir alafenamide on intestinal flora
by: Jianfei Long, et al.
Published: (2023-09-01)

Serum apolipoprotein C3 levels are negatively associated with hepatitis B virus DNA in HBeAg-negative chronic hepatitis B patients
by: Yu Cui, et al.
Published: (2019-06-01)

A Predictive Model to Evaluate the HbeAg Positivity of Chronic Hepatitis B Virus Patients in Clinics: A Cross-Sectional Study
by: Ning Wang, et al.
Published: (2022-09-01)

Response of Preterm Infants of Mothers Who Are Chronic Carriers of Both HBsAg and HBeAg to Pre-52 Containing Hepatitis 8 Vaccine (TGP 943) - A Preliminary Report
by: Abdul Hamid Sutohardjo
Published: (2018-10-01)

Residual risk of mother-to-child transmission of HBV despite timely Hepatitis B vaccination: a major challenge to eliminate hepatitis B infection in Cambodia
by: Bunthen E, et al.
Published: (2023-04-01)

Incidence and predictors of HBV functional cure in patients with HIV/HBV coinfection: A retrospective cohort study
by: Qingrong Zhang, et al.
Published: (2023-02-01)

Hepatitis B Virus e Antigen Variants
Published: (2005-01-01)

A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs: real-world clinical practice
by: Mingfan Geng, et al.
Published: (2017-09-01)

Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study
by: Yi-Cheng Chen, et al.
Published: (2020-05-01)

HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients
by: Cheng-Yuan Peng, et al.
Published: (2015-04-01)

Evaluation of the Diagnostic Performances of the SD-Bioline<sup>®</sup>HBeAg Rapid Test Used Routinely for the Management of HBV-Infected Individuals in Burkina Faso
by: Abdoulaye Dera, et al.
Published: (2023-10-01)

HBV pregenome RNA as a predictor of spontanous HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients
by: Guangjun Song, et al.
Published: (2023-11-01)

Intrahepatic transcriptomics reveals gene signatures in chronic hepatitis B patients responded to interferon therapy
by: Ning Li, et al.
Published: (2022-12-01)

Low positivity rates for HBeAg and HBV DNA in rheumatoid arthritis patients: a case–control study
by: Yue Jia, et al.
Published: (2022-06-01)

Response predictors to treatment with pegylated interferon in chronic hepatitis B
by: Paulo Roberto Abrão Ferreira, et al.

Characterization of HBeAg-negative chronic hepatitis B in western Brazilian Amazonia
by: Flamir da Silva Victoria, et al.

Serum HBV RNA quantification: useful for monitoring natural history of chronic hepatitis B infection
by: Yayun Liu, et al.
Published: (2019-04-01)

Quantitative HBsAg versus HBV DNA in Predicting Significant Hepatitis Activity of HBeAg-Positive Chronic HBV Infection
by: Zhanqing Zhang, et al.
Published: (2021-11-01)